Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Adverse event management costs for first-line treatment with cetuximab or panitumumab of RAS wild-type metastatic colorectal cancer patients in Latin America.
Authors
Chris Pescott
Merck KGaA, Darmstadt, Germany
Chris Pescott , Adam Kasle , Federico Esteso , Stephen Stefani , Leandro Brust , Jose Pinto , Malena Tilli , Matthew Massello
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Other
DOI
10.1200/JCO.2022.40.4_suppl.203
Abstract #
203
Poster Bd #
K6
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Costs of adverse event management associated with first-line cetuximab or panitumumab in patients with metastatic colorectal cancer in Spain.
First Author: Begoña Graña Suárez
Poster
2021 Gastrointestinal Cancers Symposium
Safety analysis of the randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13).
First Author: Takanori Watanabe
Poster
2021 Gastrointestinal Cancers Symposium
Cost-effectiveness of cetuximab + FOLFIRI versus bevacizumab + FOLFIRI in the first-line treatment of RAS wild-type metastatic colorectal cancer in China.
First Author: Ilse Van Oostrum
Poster
2015 Gastrointestinal Cancers Symposium
Drug cost and outcome in metastatic colorectal cancer with emphasis on monoclonal antibodies.
First Author: Helmy M. Guirgis